Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA
In royalty dispute, UK appeals court sides with GSK over AZ
Niraparib Tosylate-A Promising Treatment for Ovarian Cancer
GSK`s cancer drug combination meets primary goal in late-stage trial
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
Maintenance therapy with the PARP inhibitor niraparib (Zejula) prolonged progression-free survival (PFS) vs placebo in patients with newly diagnosed advanced ovarian cancer, according to findings from the phase 3 PRIME trial (NCT03709316) published in JAMA Oncology.­1
On August 11, 2023, the Food and Drug Administration approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test.
Janssen’s combination therapy of niraparib with abiraterone acetate plus prednisone for the treatment of BCRA-positive metastatic castration-resistant prostate cancer (mCRPC) is moving along.